{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T10:54:09Z","timestamp":1781088849758,"version":"3.54.1"},"reference-count":184,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:00:00Z","timestamp":1618444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Biosci."],"abstract":"<jats:p>Severe acute respiratory syndrome coronavirus 2, SARS-CoV-2, arose at the end of 2019 as a zoonotic virus, which is the causative agent of the novel coronavirus outbreak COVID-19. Without any clear indications of abatement, the disease has become a major healthcare threat across the globe, owing to prolonged incubation period, high prevalence, and absence of existing drugs or vaccines. Development of COVID-19 vaccine is being considered as the most efficient strategy to curtail the ongoing pandemic. Following publication of genetic sequence of SARS-CoV-2, globally extensive research and development work has been in progress to develop a vaccine against the disease. The use of genetic engineering, recombinant technologies, and other computational tools has led to the expansion of several promising vaccine candidates. The range of technology platforms being evaluated, including virus-like particles, peptides, nucleic acid (DNA and RNA), recombinant proteins, inactivated virus, live attenuated viruses, and viral vectors (replicating and non-replicating) approaches, are striking features of the vaccine development strategies. Viral vectors, the next-generation vaccine platforms, provide a convenient method for delivering vaccine antigens into the host cell to induce antigenic proteins which can be tailored to arouse an assortment of immune responses, as evident from the success of smallpox vaccine and Ervebo vaccine against Ebola virus. As per the World Health Organization, till January 22, 2021, 14 viral vector vaccine candidates are under clinical development including 10 nonreplicating and four replicating types. Moreover, another 39 candidates based on viral vector platform are under preclinical evaluation. This review will outline the current developmental landscape and discuss issues that remain critical to the success or failure of viral vector vaccine candidates against COVID-19.<\/jats:p>","DOI":"10.3389\/fmolb.2021.635337","type":"journal-article","created":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T21:22:32Z","timestamp":1618521752000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["Developmental Landscape of Potential Vaccine Candidates Based on Viral Vector for Prophylaxis of COVID-19"],"prefix":"10.3389","volume":"8","author":[{"given":"Rajashri","family":"Bezbaruah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pobitra","family":"Borah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bibhuti Bhushan","family":"Kakoti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar A.","family":"Al-Shar\u2019I","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balakumar","family":"Chandrasekaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da\u2019san M. M.","family":"Jaradat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munir A.","family":"Al-Zeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeid","family":"Abu-Romman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3390\/pathogens9030186","article-title":"Insights into the recent 2019 novel coronavirus (SARS-CoV-2) in light of past human coronavirus outbreaks","volume":"9","author":"Ashour","year":"2020","journal-title":"Pathogens"},{"key":"B2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.7150\/ijbs.52569","article-title":"Current advances in the development of SARS-CoV-2 vaccines","volume":"17","author":"Awadasseid","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/j.dsx.2020.07.022","article-title":"Vaccine development against coronavirus (2003 to present): an overview, recent advances, current scenario, opportunities and challenges","volume":"14","author":"Badgujar","year":"2020","journal-title":"Diabetes Metab. Syndr."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1038\/s41598-018-21630-4","article-title":"Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP","volume":"8","author":"Bliss","year":"2018","journal-title":"Sci. Rep."},{"key":"B5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.virol.2018.05.028","article-title":"Live-attenuated bivalent measles virus-derived vaccines targeting Middle East respiratory syndrome coronavirus induce robust and multifunctional T cell responses against both viruses in an appropriate mouse model","volume":"521","author":"Bodmer","year":"2018","journal-title":"Virology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2139\/ssrn.3564664","article-title":"Perspectives on RNA vaccine candidates for COVID-19","volume":"8","author":"Borah","year":"","journal-title":"Front. Mol. Biosci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3389\/fmolb.2021.627723","article-title":"Neurological consequences of SARS-CoV-2 infection and concurrence of treatment-induced neuropsychiatric adverse events in COVID-19 patients: navigating the uncharted","volume":"8","author":"Borah","year":"","journal-title":"Front. Mol. Biosci."},{"key":"B8","doi-asserted-by":"crossref","first-page":"284","DOI":"10.2174\/0929867327666200908113642","article-title":"Current scenario and future prospect in the management of COVID-19","volume":"28","author":"Borah","year":"2020","journal-title":"Curr. Med. Chem."},{"key":"B9","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/bjp.2008.349","article-title":"Viral vectors: from virology to transgene expression","volume":"157","author":"Bouard","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.1016\/s0140-6736(20)32156-5","article-title":"Use of adenovirus type-5 vectored vaccines: a cautionary tale","volume":"396","author":"Buchbinder","year":"2020","journal-title":"The Lancet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.31219\/osf.io\/ypgx4","article-title":"Vaccines and advanced vaccines: A landscape for advanced vaccine technology against infectious disease","volume":"12","author":"Cai","year":"2020","journal-title":"COVID-19 Tumor"},{"key":"B12","unstructured":"Draft landscape of COVID-192020"},{"key":"B13","doi-asserted-by":"publisher","first-page":"P7","DOI":"10.1164\/rccm.2014p7","article-title":"COVID-19 disease due to SARS-CoV-2 (novel coronavirus)","volume":"201","author":"Carlos","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B14","unstructured":"History of smallpox|smallpox|CDC2019"},{"key":"B15","unstructured":"Prevention and vaccine | Ebola (Ebola virus disease) | CDC2020"},{"key":"B16","unstructured":"CEPI partners with AstraZeneca to manufacture 300 million globally accessible doses of COVID-19 vaccine. CEPI2020"},{"key":"B17","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s40475-020-00201-6","article-title":"The SARS-CoV-2 vaccine pipeline: an overview","volume":"7","author":"Chen","year":"2020","journal-title":"Curr. Trop. Med. Rep."},{"key":"B18","unstructured":"Chinese Clinical Trial Register (ChiCTR)\u2014the World Health Organization international clinical trials registered organization registered platform2020"},{"key":"B19","unstructured":"Chinese Clinical Trial Register (ChiCTR)\u2014the World Health Organization international clinical trials registered organization registered platform2020"},{"key":"B20","unstructured":"CTRI\/2020\/08\/027170 ctri2020"},{"key":"B21","unstructured":"NCT03399578 Safety and immunogenicity of a candidate MERS-CoV vaccine (MERS001)\u2014No study results posted\u2014ClinicalTrials.gov"},{"key":"B22","unstructured":"NCT03615911 Safety, tolerability and immunogenicity of vaccine candidate MVA-MERS-S\u2014full text view\u2014ClinicalTrials.gov"},{"key":"B23","unstructured":"NCT04130594 Double-blind, placebo-controlled study with an open dose selection period for assessing the safety and immunogenicity of the drug \u201cBVRS-GamVac\u201d, a vector vaccine for the prevention of the Middle East respiratory syndrome, lyophilisate for the preparation of a solution for intramuscular administration, with the participation of healthy volunteers2019"},{"key":"B24","unstructured":"NCT04436276 A randomized, double-blind, placebo-controlled phase 1\/2a study to evaluate the safety, reactogenicity, and immunogenicity of Ad26COVS1 in adults aged 18 to 55 years inclusive and adults aged 65 years and older"},{"key":"B25","unstructured":"NCT04497298 A randomized, placebo-controlled trial, to evaluate the safety and immunogenicity of the COVID-19 vaccine, a measles vector-based vaccine candidate against COVID-19 in healthy volunteers consisting of an unblinded dose escalation and a blinded treatment phase"},{"key":"B26","unstructured":"NCT04498247 A phase 1\/phase 2, randomized, double-blind, placebo-controlled, dose-ranging trial to evaluate the safety, tolerability and immunogenicity of V591 (COVID-19 vaccine) in healthy younger and older participants"},{"key":"B27","unstructured":"NCT04505722 A randomized, double-blind, placebo-controlled phase 3 study to assess the efficacy and safety of Ad26.COV2.S for the prevention of SARS-CoV-2-mediated COVID-19 in adults aged 18 years and older"},{"key":"B28","unstructured":"NCT04516746 Phase III double-blind, placebo-controlled study of AZD1222 for the prevention of COVID-19 in adults\u2014full text view\u2014ClinicalTrials.gov"},{"key":"B29","unstructured":"NCT04526990 Phase III trial of A COVID-19 vaccine of adenovirus vector in adults 18 years old and above\u2014full text view\u2014ClinicalTrials.gov"},{"key":"B30","unstructured":"NCT04528641 GRAd-COV2 vaccine against COVID-19\u2014full text view\u2014ClinicalTrials.gov"},{"key":"B31","unstructured":"NCT04530396 Clinical trial of efficacy, safety, and immunogenicity of gam-COVID-vac vaccine against COVID-19\u2014full text view\u2014ClinicalTrials.gov"},{"key":"B32","unstructured":"NCT04540393 AZD1222 vaccine for the prevention of COVID-19\u2014full text view\u2014ClinicalTrials.gov"},{"key":"B33","unstructured":"NCT04540419 Clinical trial of recombinant novel coronavirus vaccine (adenovirus type 5 vector) against COVID-19\u2014full text view\u2014ClinicalTrials.gov"},{"key":"B34","unstructured":"NCT04552366 A clinical trial of a recombinant adenovirus 5 vectored COVID-19 vaccine (Ad5-nCoV) with two doses in healthy adults\u2014full text view\u2014ClinicalTrials.gov"},{"key":"B35","unstructured":"NCT04556526 A study of a 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-filo in healthy pregnant women\u2014full text view\u2014ClinicalTrials.gov2020"},{"key":"B36","unstructured":"NCT04563702 A phase 1 open-label, dose-ranging trial to determine the safety and immunogenicity of an adenoviral-vector based vaccine (VXA-CoV2-1) expressing a SARS-CoV-2 antigen and dsRNA adjuvant administered orally to healthy adult volunteers"},{"key":"B37","unstructured":"NCT04564716 Clinical trial of efficacy, safety, and immunogenicity of gam-COVID-vac vaccine against COVID-19 in Belarus\u2014full text view\u2014ClinicalTrials.gov"},{"key":"B38","unstructured":"NCT04569383 Safety, tolerability and immunogenicity of the candidate vaccine MVA-SARS-2-S against COVID-19\u2014full text view\u2014ClinicalTrials.gov"},{"key":"B39","unstructured":"NCT04569786 A phase 1, randomized, double-blind, placebo-controlled, dose-ranging trial to evaluate the safety and immunogenicity of V590 in healthy adults"},{"key":"B40","unstructured":"NCT04587219 An open study of the safety, tolerability and immunogenicity of the \u201cgam-COVID-Vac\u201dVaccine against COVID-19 (solution for intramuscular injection) with the participation of volunteers in the age group over 60 years"},{"key":"B41","unstructured":"NCT04591717 Phase 1b open-label study of the safety reactogenicity, and immunogenicity of prophylactic vaccination with 2nd generation E1\/E2B\/E3-deleted adenoviral-COVID-19 in normal healthy volunteers"},{"key":"B42","unstructured":"NCT04608305 Evaluate the safety, immunogenicity and potential efficacy of an rVSV-SARS-CoV-2-S vaccine\u2014full text view\u2014ClinicalTrials.gov"},{"key":"B43","unstructured":"NCT04614948 A randomized, double-blind, placebo-controlled phase 3 study to assess the efficacy and safety of Ad26.COV2.S for the prevention of SARS-CoV-2-mediated COVID-19 in adults aged 18 years and older"},{"key":"B44","unstructured":"NCT04642339 Randomized, double-blind, placebo controlled, clinical trial of the immunogenicity, safety, and efficacy of the gam-COVID-vac combined vector vaccine in prophylactic treatment for SARS-\u0421oV-2 infection"},{"key":"B45","unstructured":"NCT04656613 A phase III, randomized, double -blind, placebo-controlled trial to evaluate immunogenicity and safety of the gam-COVID-vac combined vector vaccine in prophylactic treatment for SARS-\u0421oV-2 infection in the United Arab Emirates. clinicaltrials.gov"},{"key":"B46","unstructured":"NCT04679909 A phase 1, double-blind, randomized, placebo-controlled, first-in-human study of the safety and immunogenicity of AdCOVID administered as one or two doses2020"},{"key":"B47","unstructured":"NCT04710303 Phase 1b open-label study of the safety, reactogenicity, and immunogenicity of a city of a prophylactiv COVID-19 vaccination using a 2nd generation E1\/E2B\/E3-Deleted adenoviral platform in healthy South African adults (ProVIVA-SA-1)2021"},{"key":"B48","unstructured":"Of the first FDA-approved vaccine for the prevention of Ebola virus disease, marking a critical milestone in public health preparedness and response\n            CommissionerO.\n          2020"},{"key":"B49","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/0140-6736(91)91636-9","article-title":"Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein","volume":"337","author":"Cooney","year":"1991","journal-title":"Lancet"},{"key":"B50","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/bs.aivir.2018.01.001","article-title":"Hosts and sources of endemic human coronavirusesAdv virus resin","volume":"100","author":"Corman","year":"2018","journal-title":"Adv. Virus Res."},{"key":"B51","unstructured":"Natl. Inst. Health NIH2020"},{"key":"B52","doi-asserted-by":"publisher","first-page":"104742","DOI":"10.1016\/j.antiviral.2020.104742","article-title":"The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade","volume":"176","author":"Coutard","year":"2020","journal-title":"Antivir. Res"},{"key":"B53","unstructured":"GRAd-COV22020"},{"key":"B54","unstructured":"Viral vector vaccine design\u2014creative Biolabs2021"},{"key":"B55","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1089\/hum.2013.2527","article-title":"Adenovirus: the first effective in vivo gene delivery vector","volume":"25","author":"Crystal","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"B56","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/d41586-020-00190-6","article-title":"This scientist hopes to test coronavirus drugs on animals in locked-down Wuhan","volume":"577","author":"Cyranoski","year":"2020","journal-title":"Nature"},{"key":"B57","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1080\/21645515.2016.1210729","article-title":"Viral vector-based influenza vaccines","volume":"12","author":"de Vries","year":"2016","journal-title":"Hum. Vaccin. Immunother."},{"key":"B58","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0889-8588(05)70245-8","article-title":"Cancer vaccines","volume":"15","author":"DeMaria","year":"2001","journal-title":"Hematol. Oncol. Clin. North. Am."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1080\/21645515.2020.1735227","article-title":"COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics","volume":"16","author":"Dhama","year":"2020","journal-title":"Hum. Vaccin. Immunother."},{"key":"B60","doi-asserted-by":"publisher","first-page":"e40385","DOI":"10.1371\/journal.pone.0040385","article-title":"A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity","volume":"7","author":"Dicks","year":"2012","journal-title":"PLoS One"},{"key":"B61","doi-asserted-by":"crossref","DOI":"10.1016\/j.chom.2020.06.020","article-title":"A replication-competent vesicular stomatitis virus for studies of SARS-CoV-2 spike-mediated cell entry and its inhibition","author":"Dieterle","year":"2020","journal-title":"Cell Host Microbe"},{"key":"B62","unstructured":"Trump administration\u2019s operation warp speed accelerates AstraZeneca COVID-19 vaccine\n            DivisionN.\n          2020"},{"key":"B63","first-page":"421","article-title":"Adenovirus-based therapy for prostate cancer","volume":"12","author":"Ekblad","year":"2010","journal-title":"Curr. Opin. Mol. Ther."},{"key":"B64","unstructured":"New vaccine for prevention of Ebola virus disease recommended for approval in the European Union | European Medicines Agency\n            EMA\n          2020"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coviro.2016.06.001","article-title":"Viral vectors as vaccine carriers","volume":"21","author":"Ertl","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"B66","unstructured":"IMLYGIC (talimogene laherparepvec) | FDA2019"},{"key":"B67","volume-title":"Smallpox and its eradication","author":"Fenner","year":"1988"},{"key":"B68","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S1473-3099(20)30160-2","article-title":"Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial","volume":"20","author":"Folegatti","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"B69","doi-asserted-by":"publisher","first-page":"S75","DOI":"10.1586\/14760584.3.4.s75","article-title":"Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors","volume":"3","author":"Franchini","year":"2004","journal-title":"Expert Rev. Vaccin."},{"key":"B70","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s10529-009-0132-0","article-title":"Potential adenovirus-mediated gene therapy of glioma cancer","volume":"32","author":"Fu","year":"2010","journal-title":"Biotechnol. Lett."},{"key":"B71","unstructured":"Merck & Co. And IAVI\u2014V590. GEN\u2014genet. Eng. Biotechnol. News\n            Gen\n          2020"},{"key":"B72","doi-asserted-by":"publisher","first-page":"11468","DOI":"10.1128\/JVI.05165-11","article-title":"The HIV\/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens","volume":"85","author":"G\u00f3mez","year":"2011","journal-title":"J. Virol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1200\/JCO.18.02031","article-title":"Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer","volume":"37","author":"Gulley","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/B978-0-12-407190-2.00007-1","article-title":"Therapeutic cancer vaccines: past, present, and future","volume":"119","author":"Guo","year":"2013","journal-title":"Adv. Cancer Res."},{"key":"B75","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/imm.12462","article-title":"Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus","volume":"145","author":"Guo","year":"2015","journal-title":"Immunology"},{"key":"B76","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40779-020-00240-0","article-title":"The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak\u2014an update on the status","volume":"7","author":"Guo","year":"2020","journal-title":"Mil. Med. Res."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1093\/infdis\/jiz137","article-title":"A highly immunogenic, protective, and safe adenovirus-based vaccine expressing Middle East respiratory syndrome coronavirus S1-CD40L fusion protein in a transgenic human dipeptidyl peptidase 4 mouse model","volume":"220","author":"Hashem","year":"2019","journal-title":"J. Infect. Dis."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/imm.12829","article-title":"Novel viral vectors in infectious diseases","volume":"153","author":"Humphreys","year":"2018","journal-title":"Immunology"},{"key":"B79","volume-title":"A phase III study to investigate a vaccine against COVID-19","year":"2020"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41577-020-0321-6","article-title":"The potential danger of suboptimal antibody responses in COVID-19","volume":"20","author":"Iwasaki","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.antiviral.2009.06.006","article-title":"Vaccinia virus vaccines: past, present and future","volume":"84","author":"Jacobs","year":"2009","journal-title":"Antivir. Res"},{"key":"B82","first-page":"31","article-title":"An inquiry into the causes and effects of the variolae vaccine","volume":"11","author":"Jenner","year":"1988","journal-title":"Chall. Epidemiol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3390\/v12040372","article-title":"Virology, epidemiology, pathogenesis, and control of COVID-19","volume":"12","author":"Jin","year":"2020","journal-title":"Viruses"},{"key":"B84","unstructured":"Johnson & Johnson announces agreement with U.S. Government for 100 million doses of investigational COVID-19 vaccine|Johnson & Johnson. Content lab US2020"},{"key":"B85","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1128\/JVI.79.2.955\u2013965.200510.1128\/JVI.79.2.955-965.2005","article-title":"Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques","volume":"79","author":"Johnson","year":"2005","journal-title":"J. Virol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"5975","DOI":"10.1016\/j.vaccine.2014.08.058","article-title":"Immunogenicity of an adenoviral-based Middle East respiratory syndrome coronavirus vaccine in BALB\/c mice","volume":"32","author":"Kim","year":"2014","journal-title":"Vaccine"},{"key":"B87","unstructured":"Single-dose intranasal administration of AdCOVID elicits systemic and mucosal immunity against SARS-CoV-2 in mice\n            KingR. G.\n            Silva-SanchezA.\n            PeelJ. N.\n            BottaD.\n            Meza-PerezS.\n            AllieS. R.\n          2020"},{"key":"B88","doi-asserted-by":"publisher","first-page":"6402","DOI":"10.1016\/j.vaccine.2012.08.018","article-title":"Effects of route and coadministration of recombinant raccoon poxviruses on immune responses and protection against highly pathogenic avian influenza in mice","volume":"30","author":"Kingstad-Bakke","year":"2012","journal-title":"Vaccine"},{"key":"B89","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/S1473-3099(20)30248-6","article-title":"Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial","volume":"20","author":"Koch","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"B90","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3389\/fmolb.2020.606393","article-title":"Combating the pandemic COVID-19: clinical trials, therapies and perspectives","volume":"7","author":"Kotta","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"B91","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1016\/j.vaccine.2009.02.006","article-title":"Safety, immunogenicity and efficacy of poxvirus-based vector vaccines expressing the haemagglutinin gene of a highly pathogenic H5N1 avian influenza virus in pigs","volume":"27","author":"Kyriakis","year":"2009","journal-title":"Vaccine"},{"key":"B92","doi-asserted-by":"publisher","first-page":"e00298","DOI":"10.1128\/CVI.00298-16","article-title":"Multivalent and multipathogen viral vector vaccines","volume":"24","author":"Lauer","year":"2017","journal-title":"Clin. Vaccin. Immunol."},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-020-03504-w","article-title":"Oxford covid-vaccine paper highlights lingering UNKNOWNS","volume":"588","author":"Ledford","year":"2020","journal-title":"Nature"},{"key":"B94","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.gendis.2017.04.001","article-title":"Adenovirus-mediated gene delivery: potential applications for gene and cell-based therapies in the new era of personalized medicine","volume":"4","author":"Lee","year":"2017","journal-title":"Genes Dis."},{"key":"B95","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jcv.2005.07.005","article-title":"Anti-SARS-CoV IgG response in relation to disease severity of severe acute respiratory syndrome","volume":"35","author":"Lee","year":"2006","journal-title":"J. Clin. Virol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1080\/22221751.2020.1830715","article-title":"Establishment of replication-competent vesicular stomatitis virus-based recombinant viruses suitable for SARS-CoV-2 entry and neutralization assays","volume":"9","author":"Li","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.cell.2020.07.012","article-title":"The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity","volume":"182","author":"Li","year":"2020","journal-title":"Cell"},{"key":"B98","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1016\/j.vaccine.2006.07.035","article-title":"Viral vectors for malaria vaccine development","volume":"25","author":"Li","year":"2007","journal-title":"Vaccine"},{"key":"B99","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1586\/14760584.6.2.255","article-title":"Use of viral vectors for the development of vaccines","volume":"6","author":"Liniger","year":"2007","journal-title":"Expert Rev. Vaccin."},{"key":"B100","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1016\/S2095-3119(17)61660-5","article-title":"Newcastle disease virus-based MERS-CoV candidate vaccine elicits high-level and lasting neutralizing antibodies in Bactrian camels","volume":"16","author":"Liu","year":"2017","journal-title":"J. Integr. Agric."},{"key":"B101","unstructured":"Here are the most promising coronavirus vaccine candidates out there|Live Science\n            Live Science\n          2020"},{"key":"B102","first-page":"87","volume-title":"Employing live microbes for vaccine delivery,\u201d in Development of Novel Vaccines","author":"Loessner","year":"2012"},{"key":"B103","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia","volume":"396","author":"Logunov","year":"2020","journal-title":"The Lancet"},{"key":"B104","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/s0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"The Lancet"},{"key":"B105","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3390\/biomedicines8050109","article-title":"Coronavirus pandemic-therapy and vaccines","volume":"8","author":"Lundstrom","year":"2020","journal-title":"Biomedicines"},{"key":"B106","doi-asserted-by":"publisher","first-page":"667","DOI":"10.2217\/fvl-2017-0070","article-title":"Latest trends in cancer therapy applying viral vectors","volume":"12","author":"Lundstrom","year":"2017","journal-title":"Future Virol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.addr.2009.04.012","article-title":"Advancements in adenoviral based virotherapy for ovarian cancer","volume":"61","author":"Matthews","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B108","first-page":"24","article-title":"Changes in the vaccinia virus through continuing passages in chick embryo fibroblast cultures","volume":"195","author":"Mayr","year":"1964","journal-title":"Zentralbl Bakteriol Orig"},{"key":"B109","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/nrmicro2613","article-title":"Influenza A viruses: new research developments","volume":"9","author":"Medina","year":"2011","journal-title":"Nat. Rev. Microbiol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-020-2607-z","article-title":"Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques","volume":"586","author":"Mercado","year":"2020","journal-title":"Nature"},{"key":"B111","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2460\/ajvr.68.2.213","article-title":"Efficacy of a canarypox-vectored recombinant vaccine expressing the hemagglutinin gene of equine influenza H3N8 virus in the protection of ponies from viral challenge","volume":"68","author":"Minke","year":"2007","journal-title":"Am. J. Vet. Res."},{"key":"B112","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41541-019-0106-8","article-title":"Recombinant measles vaccine expressing malaria antigens induces long-term memory and protection in mice","volume":"4","author":"Mura","year":"2019","journal-title":"Npj Vaccin."},{"key":"B113","doi-asserted-by":"publisher","first-page":"410","DOI":"10.2174\/156652312802762518","article-title":"Development of Sendai virus vectors and their potential applications in gene therapy and regenerative medicine","volume":"12","author":"Nakanishi","year":"2012","journal-title":"Curr. Gene Ther."},{"key":"B114","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.ymthe.2019.03.008","article-title":"Lentiviral vector-based dendritic cell vaccine suppresses HIV replication in humanized mice","volume":"27","author":"Norton","year":"2019","journal-title":"Mol. Ther."},{"key":"B115","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1086\/515331","article-title":"Phase I\/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria","volume":"177","author":"Ockenhouse","year":"1998","journal-title":"J. Infect. Dis."},{"key":"B116","doi-asserted-by":"publisher","first-page":"286re5","DOI":"10.1126\/scitranslmed.aaa2373","article-title":"Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults","volume":"7","author":"Ogwang","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"B117","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1128\/CDLI.10.3.411\u2013416.200310.1128\/cdli.10.3.411-416.2003","article-title":"Frequency of measles virus-specific CD4+ and CD8+ T cells in subjects seronegative or highly seropositive for measles vaccine","volume":"10","author":"Ovsyannikova","year":"2003","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40121-020-00300-x","article-title":"Vaccines for SARS-CoV-2: lessons from other coronavirus strains","volume":"9","author":"Padron-Regalado","year":"2020","journal-title":"Infect. Dis. Ther."},{"key":"B119","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1097\/COH.0b013e32833d1e87","article-title":"Poxvirus vector-based HIV vaccines","volume":"5","author":"Pantaleo","year":"2010","journal-title":"Curr. Opin. HIV AIDS"},{"key":"B120","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.jaci.2006.09.037","article-title":"Smallpox vaccines: past, present, and future","volume":"118","author":"Parrino","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"B121","article-title":"Ervebo (Ebola Zaire vaccine, live\/rVSV\u0394G-ZEBOV-GP): the first licensed vaccine for the prevention of Ebola virus disease","volume":"36","author":"Piszczatoski","year":"2020","journal-title":"J. Pharm. Technol."},{"key":"B122","unstructured":"Ad5-nCoV COVID-19 vaccine"},{"key":"B123","unstructured":"Ad5-nCoV SARS-CoV-2 vaccine"},{"key":"B124","unstructured":"AZD1222 SARS-CoV-2 vaccine"},{"key":"B125","doi-asserted-by":"publisher","first-page":"6436","DOI":"10.1016\/j.vaccine.2016.06.059","article-title":"Vector-based genetically modified vaccines: exploiting Jenner's legacy","volume":"34","author":"Ramezanpour","year":"2016","journal-title":"Vaccine"},{"key":"B126","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1473-3099(15)70043-5","article-title":"Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial","volume":"15","author":"Ramsauer","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"B127","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.3389\/fimmu.2018.01963","article-title":"New vaccine technologies to combat outbreak situations","volume":"9","author":"Rauch","year":"2018","journal-title":"Front. Immunol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"Rerks-Ngarm","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1101\/2020.07.29.227595","article-title":"A next generation bivalent human Ad5 COVID-19 vaccine delivering both spike and nucleocapsid antigens elicits Th1 dominant CD4+, CD8+ T-cell and neutralizing antibody responses","author":"Rice","year":"2020"},{"key":"B130","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.copbio.2007.10.010","article-title":"Replicating and non-replicating viral vectors for vaccine development","volume":"18","author":"Robert-Guroff","year":"2007","journal-title":"Curr. Opin. Biotechnol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1084\/jem.137.4.1091","article-title":"Induction of arginase activity with the Shope papilloma virus in tissue culture cells from an argininemic patient","volume":"137","author":"Rogers","year":"1973","journal-title":"J. Exp. Med."},{"key":"B132","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.coi.2011.03.006","article-title":"Viral vectors as vaccine platforms: deployment in sight","volume":"23","author":"Rollier","year":"2011","journal-title":"Curr. Opin. Immunol."},{"key":"B133","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1358\/dnp.2005.18.5.917326","article-title":"Current development of adeno-associated viral vectors","volume":"18","author":"Romano","year":"2005","journal-title":"Drug News Perspect."},{"key":"B134","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S1473-3099(10)70069-4","article-title":"Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference","volume":"10","author":"Ross","year":"2010","journal-title":"Lancet Infect. Dis."},{"key":"B135","doi-asserted-by":"crossref","DOI":"10.1101\/2020.06.27.175166","article-title":"Modified vaccinia Ankara based SARS-CoV-2 vaccine expressing full-length spike induces strong neutralizing antibody response","author":"Routhu","year":"2020"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1101\/2020.09.23.20199604","article-title":"Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1\/2a, double-blind, randomized, placebo-controlled trial","author":"Sadoff","year":"2020"},{"key":"B137","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2174\/1570162053506900","article-title":"Non-replicating viral vector-based AIDS vaccines: interplay between viral vectors and the immune system","volume":"3","author":"Sauter","year":"2005","journal-title":"Curr. HIV Res."},{"key":"B138","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nm0498-397","article-title":"Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara","volume":"4","author":"Schneider","year":"1998","journal-title":"Nat. Med."},{"key":"B139","unstructured":"Solutions to the complex cold storage paradigm | selectScience2021"},{"key":"B140","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1089\/hum.2011.2517","article-title":"Adenovirus: teaching an old dog new tricks","volume":"22","author":"Seymour","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"B141","doi-asserted-by":"publisher","first-page":"38581","DOI":"10.18632\/oncotarget.16934","article-title":"Selective eradication of cancer cells by delivery of adenovirus-based toxins","volume":"8","author":"Shapira","year":"2017","journal-title":"Oncotarget"},{"key":"B142","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/0042-6822(87)90004-3","article-title":"Synthesis and cellular location of the ten influenza polypeptides individually expressed by recombinant vaccinia viruses","volume":"160","author":"Smith","year":"1987","journal-title":"Virology"},{"key":"B143","doi-asserted-by":"publisher","first-page":"7155","DOI":"10.1073\/pnas.80.23.7155","article-title":"Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters","volume":"80","author":"Smith","year":"1983","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"B144","doi-asserted-by":"publisher","first-page":"11950","DOI":"10.1128\/JVI.01672-13","article-title":"Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies","volume":"87","author":"Song","year":"2013","journal-title":"J. Virol."},{"key":"B145","unstructured":"AstraZeneca Covid-19 vaccine study is put on hold. STAT\n            Stat\n          2020"},{"key":"B146","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2174\/1568005033481123","article-title":"Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery","volume":"3","author":"Sutter","year":"2003","journal-title":"Curr. Drug Targets Infect. Disord."},{"key":"B147","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1128\/JVI.02055-12","article-title":"Comparative analysis of simian immunodeficiency virus gag-specific effector and memory CD8+ T cells induced by different adenovirus vectors","volume":"87","author":"Tan","year":"2013","journal-title":"J. Virol."},{"key":"B148","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1089\/vim.2005.18.317","article-title":"Live attenuated measles vaccine as a potential multivalent pediatric vaccination vector","volume":"18","author":"Tangy","year":"2005","journal-title":"Viral Immunol."},{"key":"B149","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1473-3099(15)00362-X","article-title":"Use of Chad3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial","volume":"16","author":"Tapia","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"B150","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/0264-410x(88)90101-6","article-title":"Protective immunity against avian influenza induced by a fowlpox virus recombinant","volume":"6","author":"Taylor","year":"1988","journal-title":"Vaccine"},{"key":"B151","unstructured":"Vector-based vaccines come to the fore in the COVID-19 pandemic. Sci Mag\n            The Scientist\n          2020"},{"key":"B152","unstructured":"Covishield update: Oxford COVID-19 vaccine may be ready by December, says Serum Institute CEO2020"},{"key":"B153","doi-asserted-by":"publisher","first-page":"e0208328","DOI":"10.1371\/journal.pone.0208328","article-title":"First field efficacy trial of the Chad63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children","volume":"13","author":"Tiono","year":"2018","journal-title":"PLoS One"},{"key":"B154","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1038\/s41591-020-1070-6","article-title":"Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters","volume":"26","author":"Tostanoski","year":"2020","journal-title":"Nat. Med."},{"key":"B155","unstructured":"2020"},{"key":"B156","doi-asserted-by":"publisher","first-page":"9244","DOI":"10.1128\/JVI.00945-06","article-title":"Genome of horsepox virus","volume":"80","author":"Tulman","year":"2006","journal-title":"J. Virol."},{"key":"B157","doi-asserted-by":"publisher","first-page":"624","DOI":"10.3390\/vaccines2030624","article-title":"Developments in viral vector-based vaccines","volume":"2","author":"Ura","year":"2014","journal-title":"Vaccines (Basel)"},{"key":"B158","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1089\/10430340260355347","article-title":"Insect cells as a factory to produce adeno-associated virus type 2 vectors","volume":"13","author":"Urabe","year":"2002","journal-title":"Hum. Gene Ther."},{"key":"B159","unstructured":"ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques\n            van DoremalenN.\n            LambeT.\n            SpencerA.\n            Belij-RammerstorferS.\n            PurushothamJ. N.\n            PortJ. R.\n          2020"},{"key":"B160","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/s41563-020-0746-0","article-title":"Next-generation vaccine platforms for COVID-19","volume":"19","author":"van Riel","year":"2020","journal-title":"Nat. Mater."},{"key":"B161","unstructured":"Oral vaccines\u2014Vaxart Inc\n            Vaxart\n          2020"},{"key":"B162","doi-asserted-by":"publisher","first-page":"718","DOI":"10.3390\/v10120718","article-title":"CD8+ T cells responding to the middle east respiratory syndrome coronavirus nucleocapsid protein delivered by vaccinia virus MVA in mice","volume":"10","author":"Veit","year":"2018","journal-title":"Viruses"},{"key":"B163","doi-asserted-by":"publisher","first-page":"8651","DOI":"10.1128\/JVI.00614-15","article-title":"Protective efficacy of recombinant modified vaccinia virus Ankara delivering Middle East respiratory syndrome coronavirus spike glycoprotein","volume":"89","author":"Volz","year":"2015","journal-title":"J. Virol."},{"key":"B164","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"The Lancet"},{"key":"B165","unstructured":"2_Ebola_SAGE2018Oct_BgDoc_20180919.pdf\n            Who\n          2018"},{"key":"B166","unstructured":"Clinical management of COVID-19\n            Who"},{"key":"B167","unstructured":"Draft landscape and tracker of COVID-19 candidate vaccines\n            Who\n          2021"},{"key":"B168","unstructured":"Draft landscape of COVID-19 candidate vaccines\n            Who"},{"key":"B169","unstructured":"Ebola virus disease\n            Who"},{"key":"B170","unstructured":"HIV\/AIDS\n            Who"},{"key":"B171","unstructured":"List-of-candidate.-vaccines-developed-against-sars.pdf\n            Who"},{"key":"B172","unstructured":"WHO coronavirus disease (COVID-19) dashboard\n            WHO"},{"key":"B173","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2174\/1566523213666131125095046","article-title":"Adenovirus vectors for gene therapy, vaccination and cancer gene therapy","volume":"13","author":"Wold","year":"2013","journal-title":"Curr. Gene Ther."},{"key":"B174","doi-asserted-by":"publisher","first-page":"3994","DOI":"10.1128\/JVI.73.5.3994-4003.1999","article-title":"Gene therapy vectors based on adeno-associated virus type 1","volume":"73","author":"Xiao","year":"1999","journal-title":"J. Virol."},{"key":"B175","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1080\/21645515.2020.1820808","article-title":"Recombinant vaccines for COVID-19","volume":"16","author":"Yadav","year":"2020","journal-title":"Hum. Vaccin. Immunother."},{"key":"B176","unstructured":"A single dose of recombinant VSV-\u2206 G-spike vaccine provides protection against SARS-CoV-2 challenge\n            Yahalom-RonenY.\n            TamirH.\n            MelamedS.\n            PolitiB.\n            ShifmanO.\n            AchdoutH.\n          2020"},{"key":"B177","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.3389\/fmicb.2019.01781","article-title":"Recent advances in the vaccine development against Middle East respiratory syndrome-coronavirus","volume":"10","author":"Yong","year":"2019","journal-title":"Front. Microbiol."},{"key":"B178","article-title":"The fight against the 2019-nCoV outbreak: an arduous march has just begun","volume":"35","author":"Yoo","year":"2019","journal-title":"J. Korean Med. Sci."},{"key":"B179","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.micinf.2020.01.003","article-title":"Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China","volume":"22","author":"Yu","year":"2020","journal-title":"Microbes Infect."},{"key":"B180","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1080\/21645515.2020.1787064","article-title":"Perspectives on development of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","volume":"16","author":"Zhang","year":"2020","journal-title":"Hum. Vaccin. Immunother."},{"key":"B181","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3390\/vaccines8020153","article-title":"Progress and prospects on vaccine development against SARS-CoV-2","volume":"8","author":"Zhang","year":"2020","journal-title":"Vaccines"},{"key":"B182","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/s0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"","journal-title":"The Lancet"},{"key":"B183","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"","journal-title":"The Lancet"},{"key":"B184","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1016\/j.vaccine.2007.01.064","article-title":"Attenuated measles virus as a vaccine vector","volume":"25","author":"Zuniga","year":"2007","journal-title":"Vaccine"}],"container-title":["Frontiers in Molecular Biosciences"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2021.635337\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T21:24:19Z","timestamp":1618521859000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2021.635337\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,15]]},"references-count":184,"alternative-id":["10.3389\/fmolb.2021.635337"],"URL":"https:\/\/doi.org\/10.3389\/fmolb.2021.635337","relation":{},"ISSN":["2296-889X"],"issn-type":[{"value":"2296-889X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,15]]},"article-number":"635337"}}